Caplin Point Laboratories Ltd.

“Caplin Point is a rare high-ROIC, debt-free compounder with a durable Latin American branded generics moat built on 2,000+ product registrations and a proprietary distribution network that would take a decade to replicate. EPS has compounded at ~21% annually over four years with zero dilution and zero leverage, driven by a founder-operator holding 60% with no pledging. The second growth engine — Caplin Steriles, an FDA-regulated injectable platform — is now largely built and beginning to generate US revenue, representing meaningful upside optionality if execution materialises over the next 3–5 years. At 22x forward earnings, the stock prices in continued compounding but offers no margin of safety for the unproven US business or the key-man concentration risk; the embedded IRR of ~12% is reasonable for the quality but not asymmetric enough for a high-conviction BUY. The single credible permanent-impairment risk is an FDA enforcement action on Caplin Steriles; all other risks — LatAm currency, geopolitical exposure — represent manageable uncertainty over a 5–10 year horizon. At 18–20x forward earnings, this becomes a compelling BUY with a credible 3–4x base case over a decade.”